InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds
- Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compounds Patent covers novel analog compounds for therapeutic applications in pain, glaucoma, inflammatory disease, anxiety, and a variety of neurological conditions including Parkinson's disease, Alzheimer's disease and dementia Patent also protects the methods of preparation of the compounds Vancouver, British Columbia--(Newsfile Corp. - January 22, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces it has been granted an international Patent Cooperation Treaty ('PCT') patent in the first of several jurisdictions where the patent has been filed. Titled "Cannabinoid analogs and methods for their preparation ", this patent protects the use of several proprietary small molecule compounds and methods of their preparation, including the drug candidates screened for InMed's Alzheimer's disease and dry age-related macular degeneration programs.
- 01/22/2025
|
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study
- INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer's Statistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL') mRNA profile showed a reduction of several key neuroinflammatory genes in the brain Vancouver, British Columbia--(Newsfile Corp. - January 21, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces positive results from a long-term in vivo preclinical Alzheimer's Disease ('AD') study. In the study, INM-901 demonstrated a reduction in several plasma and brain markers of neuroinflammation, a recognized contributor to Alzheimer's disease development and progression.
- 01/21/2025
|
InMed Announces Results of 2024 Annual General Meeting
- Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirmed that, at its annual general meeting of shareholders held on December 18, 2024 (the "Meeting"), the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 28, 2024, were voted upon by the shareholders. A total of 5,318,677 common shares of the Company, representing approximately 39.83% of the Company's 13,353,431 issued and outstanding common shares, were represented in person or by proxy at the Meeting.
- 12/18/2024
|
InMed Enters Into Standby Equity Purchase Agreement
- Vancouver, British Columbia--(Newsfile Corp. - December 17, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announces it entered into a Standby Equity Purchase Agreement (the "SEPA") with YA II PN, LTD (the "Investor"), an investment fund managed by Yorkville Advisors Global LP, a global investment manager, on December 13, 2024 (the "Effective Date") to sell up to $10 million in the aggregate of the Company's common shares, no value (the "Common Shares"), at any time during the 36-month period following the Effective Date of the SEPA, subject to the effectiveness of a registration statement with the Securities and Exchange Commission and other conditions set forth in the SEPA. "This equity facility is a key component of our financing strategy, offering both flexibility and extended runway to accelerate our pharmaceutical programs and other business development initiatives," said Eric A.
- 12/17/2024
|
InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System
- Cannabinol modulates distinct endocannabinoid system elements and exerts anti-inflammatory effects Supports therapeutic potential of cannabinol for inflammatory skin diseases such as psoriasis, atopic dermatitis and pruritus Anti-inflammatory effects of cannabinol show potential for therapeutic and cosmetic application Vancouver, British Columbia--(Newsfile Corp. - November 19, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that a peer-reviewed scientific study entitled "Cannabinol modulates the endocannabinoid system and shows TRPV1-mediated anti-inflammatory properties in human keratinocytes" has been published in the international journal Biofactors. This Company-sponsored study demonstrates the biological activity of cannabinol ("CBN") and its potential anti-inflammatory effects in skin diseases.
- 11/19/2024
|
InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update
- Vancouver, British Columbia--(Newsfile Corp. - November 14, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today reports financial results for the first quarter of the fiscal year 2025 which ended September 30, 2024. The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
- 11/14/2024
|
InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules
- Vancouver, British Columbia--(Newsfile Corp. - November 8, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced, pursuant to a directors' resolution, InMed will be consolidating all of its issued and outstanding share capital on the basis of one (1) post‐consolidation share for each twenty (20) pre‐consolidation common shares, no par value, of the Company (the "Common Shares") in order to regain compliance with all of Nasdaq's continued listing requirements (the "Consolidation"). The Consolidation will result in the number of issued and outstanding Common Shares being reduced from 14,361,550 to approximately 718,078 Common Shares on a non-diluted basis, and each shareholder will hold the same percentage of Common Shares outstanding immediately after the Consolidation as such shareholder held immediately prior to the Consolidation.
- 11/08/2024
|
InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules
- Vancouver, British Columbia--(Newsfile Corp. - November 5, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the decision by the Nasdaq Listing Qualifications Panel (the "Panel") to grant an exception until December 2, 2024, to implement a share consolidation to satisfy the Nasdaq Listing Rules. As previously reported by InMed on its current report on Form 8-K, on September 17, 2024, the Listing Qualifications Department (the "Nasdaq Staff") of the Nasdaq Stock Market ("Nasdaq") issued a determination to the Company, which was communicated through a delisting notice (the "Delisting Notice"), indicating that the Company did not satisfy the minimum $1.00 bid price per share requirement for the continued listing on Nasdaq, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule") by September 16, 2024.
- 11/05/2024
|
InMed Pharmaceuticals Files Additional Patent Application for INM-901 in the Treatment of Neurodegenerative Conditions Including Alzheimer's Disease
- Vancouver, British Columbia--(Newsfile Corp. - October 28, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, announced that it has filed an additional international patent application, under the Patent Cooperation Treaty (PCT), focused on the pharmaceutical composition and method of use for the proprietary small molecule drug candidate INM-901 for treating neurodegenerative diseases, including Alzheimer's disease. This PCT patent application encompasses several key components, including: treatment of neuronal disorders, particularly those associated with neurodegeneration; potential to inhibit or slow the progression of neurodegenerative diseases by reducing cytotoxicity in affected neuron populations; and use in promoting neurite elongation and/or restoring neurite formation in damaged neurons.
- 10/28/2024
|
InMed to Participate in Fierce Biotech Webinar on Neuroinflammation in Alzheimer's Disease
- Vancouver, British Columbia--(Newsfile Corp. - October 24, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it will be participating in the upcoming Fierce Biotech webinar "Alzheimer's Outlook - Neuroinflammation, the Next Step," on November 12th, 2024. InMed's Senior Vice President of Preclinical Research and Development, Dr. Eric Hsu, will join a panel of experts to speak about recent trends in Alzheimer's disease research and the targeting of neuroinflammation to restrict disease progression.
- 10/24/2024
|
InMed Appoints Dr. Barry Greenberg, Johns Hopkins University School of Medicine, to its Scientific Advisory Board
- Vancouver, British Columbia--(Newsfile Corp. - October 22, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced the appointment of Dr. Barry Greenberg to its Scientific Advisory Board. Dr. Greenberg is the Director of the Alzheimer's Disease Translational Center and an Associate Professor in the Department of Neurology at the Johns Hopkins University School of Medicine.
- 10/22/2024
|
InMed Pharmaceuticals Reports Full Year Fiscal 2024 Financial Results and Provides Business Update
- Advances INM-901 program targeting several biological pathways associated with Alzheimer's disease Further develops INM-089 demonstrating neuroprotection in the treatment of dry Age-related Macular Degeneration $4.6M revenues in fiscal year 2024, representing a 11% increase over the previous fiscal year Vancouver, British Columbia--(Newsfile Corp. - September 30, 2024) - InMed Pharmaceuticals Inc. (Nasdaq: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced financial results for the fiscal year ending June 30, 2024 and provided a business update on the pharmaceutical drug development programs as well as the commercial segment for its wholly-owned subsidiary, BayMedica, LLC ("BayMedica"). The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2024, are available at www.inmedpharma.com and at www.sedar.com.
- 09/30/2024
|
InMed Receives NASDAQ Delisting Notice, and Confirms it has Filed an Appeal and Obtained a Panel Hearing Date
- Vancouver, British Columbia--(Newsfile Corp. - September 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced that it has timely requested a hearing (the "Hearing") before the Nasdaq Listing Qualifications Panel (the "Panel") to appeal (the "Appeal") the determination by the Listing Qualifications Department (the "Nasdaq Staff") of The Nasdaq Stock Market LLC ("Nasdaq"), and present its plan to regain and sustain compliance with Nasdaq's minimum bid price requirement of at least $1.00 for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). Nasdaq has notified the Company via electronic mail that the Hearing has been scheduled for October 31, 2024.
- 09/20/2024
|
InMed Pharmaceuticals Strengthens Patent Portfolio with Issuance of Three U.S. Patents
- InMed's intellectual property portfolio totals 13 patent families covering new chemical entities, formulations, manufacturing methods and methods of use Vancouver, British Columbia--(Newsfile Corp. - August 21, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced it has been issued three U.S. patents: one for its formulation and method of use in the treatment of epidermolysis bullosa and related connective tissue disorders, one for biosynthesis manufacturing processes and one for an ocular drug delivery formulation. The method of use patent, entitled "Use of topical formulations of cannabinoids in the treatment of epidermolysis bullosa and related connective tissue disorders" relates to INM-755 drug candidate which has completed a Phase 2 clinical trial in the treatment of symptoms related to epidermolysis bullosa.
- 08/21/2024
|
InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday
- On Tuesday, InMed Pharmaceuticals Inc. INM confirmed INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer's disease.
- 08/20/2024
|
InMed Pharmaceuticals Demonstrates INM-901 as an Oral Formulation Targeting Alzheimer's Disease
- High bioavailability of INM-901 oral formulation provides similar drug concentration levels in the brain as intraperitoneal (IP) injection Vancouver, British Columbia--(Newsfile Corp. - August 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today confirms INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer's disease. Recent preclinical studies have demonstrated that INM-901, a proprietary small molecule drug candidate, can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through intraperitoneal ("IP") injection, which is a common route of administration for preclinical investigation of neurodegenerative diseases.
- 08/20/2024
|
InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical Alzheimer's Disease Study, Confirming Previous Short-Term Pilot Study Data
- Results confirm improvements in cognitive function, memory and locomotor activity Achieved statistical significance in certain behavioral assessments Additional molecular analyses ongoing to elucidate INM-901 mechanisms of action Vancouver, British Columbia--(Newsfile Corp. - July 30, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announced positive results from initial data sets from a long-term (7 months of dosing) in vivo preclinical Alzheimer's Disease ("AD") study of INM-901 which confirms previously reported findings from a short-term (3 months of dosing) pilot study, as disclosed in the Company's prior press release dated April 4, 2024. Similar to the short-term pilot study, this long-term dosing study was conducted using the 5xFAD amyloidosis model with extended dosing duration and increased sample size as compared to the short-term study.
- 07/30/2024
|
InMed to Present at the Emerging Growth Conference
- Vancouver, British Columbia--(Newsfile Corp. - June 10, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced the Company will be presenting at the upcoming Emerging Growth Conference scheduled for June 12-13, 2024. InMed's CEO, Mr.
- 06/10/2024
|
InMed Pharmaceuticals Reports Third Quarter Fiscal 2024 Financial Results and Provides Business Update
- Reported positive preclinical data in both its Alzheimer's and dry AMD programs Closed Fiscal Q3 with cash position of US$7.9 million Vancouver, British Columbia--(Newsfile Corp. - May 14, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates, today announced financial results and business update for the third quarter of the fiscal year 2024, which ended March 31, 2024. The Company's full financial statements and related MD&A for the third quarter ended March 31, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
- 05/14/2024
|
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
- Vancouver, British Columbia--(Newsfile Corp. - April 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the addition of Dr. David G. Morgan, a renowned leader in neurodegenerative disease to its Scientific Advisory Board ("SAB") reinforcing the Company's commitment to advancing it's INM-901 program in the treatment of Alzheimer's disease.
- 04/18/2024
|
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
- Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Vancouver, British Columbia--(Newsfile Corp. - April 16, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical data for INM-089 further demonstrating positive pharmacological effects targeting dry Age-Related Macular Degeneration ("AMD"). Dr. Eric Hsu, SVP of Preclinical Research and Development, stated, "We are very excited with the data from recent preclinical studies demonstrating both significant functional and pathological improvements from INM-089 in the AMD model.
- 04/16/2024
|
InMed's INM-901 Demonstrates Favorable Pharmacological and Behavioral Effects in In Vivo Preclinical Alzheimer's Disease Studies
- INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function Molecular analysis data further explains previously reported observations in behavioral studies on locomotion, memory and cognition Vancouver, British Columbia--(Newsfile Corp. - April 4, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced additional preclinical data demonstrating INM-901's positive pharmacological effects in the potential treatment of Alzheimer's disease ("AD"). Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed, stated, "The recent results demonstrating pharmacological effects in in vivo disease models continue to validate INM-901 as a potential treatment of AD.
- 04/04/2024
|
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
- Vancouver, British Columbia--(Newsfile Corp. - March 20, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced that it has received a notification letter from the Listing Qualifications Department of Nasdaq Stock Market LLC ("Nasdaq") that the Company has been granted an additional 180-day compliance period, or until September 16, 2024 (the "Extended Compliance Period"), to regain compliance with Nasdaq's minimum bid price requirement for the continued listing on the Nasdaq Capital Market, as set forth in Nasdaq Listing Rule 5550(a)(2) (the "Minimum Bid Price Rule"). Nasdaq's determination is based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market, with the exception of the bid price requirement, and the Company's written notice of its intention to consider all available options to regain compliance during the Extended Compliance Period, including, if necessary, effecting a reverse stock split.
- 03/20/2024
|
InMed Reports Second Fiscal Quarter 2024 Financial Results and Provides Business Update
- Advancing two new preclinical programs in Alzheimer's and Age-Related Macular Degeneration Closed calendar year 2023 with cash position of US$9.5 million 164% revenue growth in the commercial BayMedica subsidiary Vancouver, British Columbia--(Newsfile Corp. - February 13, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today reports financial results for the second quarter of the fiscal year 2024 which ended December 31, 2023. The Company's full financial statements and related MD&A for the second quarter ended December 31, 2023, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
- 02/13/2024
|
InMed Pharmaceuticals Strengthens Executive Leadership Team with Appointment of Ms. Netta Jagpal as Chief Financial Officer
- Vancouver, British Columbia--(Newsfile Corp. - February 9, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today announced the appointment of Ms. Netta Jagpal, CPA, CA as Chief Financial Officer and Corporate Secretary, effective February 20, 2024.
- 02/09/2024
|
InMed to Discuss Its Pharmaceutical Pipeline and 2024 Strategic Priorities in Fireside Chat with Water Tower Research on January 25, 2024 at 1pm ET
- Vancouver, British Columbia--(Newsfile Corp. - January 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, will be participating in the Water Tower Research Fireside Chat Series on January 25, 2024, at 1:00 pm ET. This event is open access for all investors.
- 01/18/2024
|
InMed Pharmaceuticals Provides Business Update and Milestones for 2024
- Advancing INM-901 as a multimodal treatment option for Alzheimer's Disease Advancing INM-089 in the treatment of Age-related Macular Degeneration Actively seeking partnerships to advance INM-755 in Dermatology BayMedica subsidiary continues to focus on revenue growth and market expansion Vancouver, British Columbia--(Newsfile Corp. - January 16, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs, today outlines key accomplishments from 2023 and provides key strategic priorities for 2024. Eric A. Adams, InMed President and CEO, commented, "In 2023, we experienced significant progress in both InMed's pharmaceutical drug development and in BayMedica's health and wellness initiatives.
- 01/16/2024
|
InMed Announces Results of 2023 Annual General Meeting
- Vancouver, British Columbia--(Newsfile Corp. - December 19, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development and manufacturing of rare cannabinoids and cannabinoid analogs, today confirmed that, at its annual general meeting of shareholders held on December 19, 2023 (the "Meeting"), all of the matters put forward before shareholders for consideration and approval as set out in InMed's notice of meeting and management information circular, dated October 27, 2023, were approved by the shareholders. A total of 1,292,647 common shares of the Company, representing approximately 38.84% of the Company's 3,328,191 issued and outstanding common shares, were represented in person or by proxy at the Meeting.
- 12/19/2023
|
InMed Reports First Quarter Fiscal 2024 Financial Results and Provides Business Update
- Vancouver, British Columbia--(Newsfile Corp. - November 14, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today reports financial results for the first quarter of the fiscal year 2024 which ended September 30, 2023. The Company's full financial statements and related MD&A for the first quarter ended September 30, 2023, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.
- 11/14/2023
|
InMed Announces Presentation of INM-755 Phase 2 Clinical Study Results at 12th World Congress on Itch (WCI) 2023
- Vancouver, British Columbia--(Newsfile Corp. - November 2, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that an abstract describing the Phase 2 clinical study of investigational drug INM-755 cannabinol ("CBN") cream for the treatment of symptoms in patients with epidermolysis bullosa ("EB"), a rare genetic skin disease, has been accepted as an oral presentation at the 12th World Congress on Itch (WCI), being held in Miami on November 5-7, 2023. Presentation details are below: Abstract Title: INM-755 cannabinol cream demonstrates anti-itch activity in patients with epidermolysis bullosa Presenting Author: Alexandra Mancini, Senior Vice President, Clinical and Regulatory Affairs, InMed Pharmaceutical Inc. Session: Hot Topics Date/Time: Tuesday, November 7 at 4:08 PM ET The Phase 2 Study: The Phase 2 study was designed to evaluate the safety of INM-755 CBN cream, which consists of the control cream plus the active pharmaceutical ingredient CBN, and obtain preliminary evidence of efficacy in treating symptoms and healing wounds over a 28-day period in patients with EB.
- 11/02/2023
|
InMed Pharmaceuticals Announces the Closing of $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market Under Nasdaq Rules
- Vancouver, British Columbia--(Newsfile Corp. - October 26, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that it has closed its previously announced offering for the issuance and sale of 3,012,049 pre-funded warrants and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per pre-funded and associated preferred investment option in a private placement priced at-the-market under Nasdaq rules (the "private placement"). Pursuant to a previously announced definitive agreement with respect to certain of its outstanding preferred investment options issued in November 2022 and exercisable for 3,272,733 common shares, in the aggregate, the holders of such outstanding preferred investment options have exercised such preferred investment options for cash at a reduced exercise price of $0.83 per share, in exchange for unregistered new preferred investment options to purchase up to 6,545,466 common shares (the "preferred investment option exercise" and, collectively with the private placement, the "offerings").
- 10/26/2023
|
Why Is InMed Pharmaceuticals (INM) Stock Down 25% Today?
- InMed Pharmaceuticals (NASDAQ: INM ) stock is falling on Wednesday after the pharmaceutical company's shares underwent a massive rally on Tuesday! INM stock was up 70.5% when normal trading hours ended on Tuesday.
- 10/25/2023
|
InMed Pharmaceuticals Announces $5.2 Million Private Placement and Preferred Investment Option Exercise Priced At-the-Market under Nasdaq Rules
- Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced that it has entered into definitive agreements for the issuance and sale of 3,012,049 of its common shares (or pre-funded warrants in lieu thereof) and preferred investment options to purchase up to an aggregate of 3,012,049 common shares, at a purchase price of $0.83 per share (or pre-funded warrant in lieu thereof) and associated preferred investment option in a private placement priced at-the-market under Nasdaq rules (the "private placement"). The Company has also entered into a definitive agreement with respect to certain of its outstanding preferred investment options issued in November 2022 and exercisable for 3,272,733 common shares, in the aggregate, to exercise such preferred investment options for cash at a reduced exercise price of $0.83 per share, in exchange for unregistered new preferred investment options to purchase up to 6,545,466 common shares (the "preferred investment option exercise" and, collectively with the private placement, the "offerings").
- 10/24/2023
|
Why Is InMed (INM) Stock Up 110% Today?
- Investors have seen some impressive moves in recent days in the world of micro-cap biotech stocks. Today, InMed (NASDAQ: INM ) is among the leading gainers in the market, surging more than 110% as of this writing.
- 10/24/2023
|
InMed Pharmaceuticals Inc.'s INM-901 Demonstrates Unique Pharmacological Effects in Alzheimer's Disease in Preclinical Proof-of-Concept Studies
- In vitro Alzheimer's disease studies show that INM-901 treated groups display neuroprotection and extended neurite length, a potential marker for improved neuronal function INM-901 treated groups in an in vivo Alzheimer's disease model demonstrate improved behavioral, cognitive and memory outcomes in several Alzheimer's proof-of-concept studies Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced it has selected a lead Alzheimer's disease drug candidate, named INM-901, following positive results from several proof-of-concept studies in a validated Alzheimer's disease treatment model. InMed will be advancing INM-901, a cannabinoid analog, in its pharmaceutical drug development program.
- 10/24/2023
|
InMed Pharmaceuticals Reports Full Year Fiscal 2023 Financial Results and Provides Business Update
- Completed Phase 2 Clinical Trial demonstrating anti-itch activity of INM-755 (CBN) topical cream $4.1M revenues in fiscal year 2023, representing a 280% increase over the previous fiscal year and $2.3M revenues in fiscal Q4 2023, representing 123% increase quarter over quarter ("QoQ") Strengthens pharmaceutical pipeline with launch of INM-900 series program targeting neurodegenerative diseases such as Alzheimer's Vancouver, British Columbia--(Newsfile Corp. - September 29, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced financial results for the fiscal year ending June 30, 2023 and provided a business update on the pharmaceutical drug development programs as well as the commercial segment for a wholly-owned subsidiary, BayMedica, LLC ("BayMedica"). The Company's full financial statements and related MD&A for the fiscal year ended June 30, 2023, are available at www.inmedpharma.com and at www.sedarplus.ca.
- 09/29/2023
|
InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance
- Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing and commercialization of rare cannabinoids and cannabinoid analogs, today announced the Company received written notice from the listing qualifications department staff of The Nasdaq Capital Market ("Nasdaq") dated September 19, 2023, notifying that the closing bid price of the Company's common shares over a period of 30 consecutive trading days was below the minimum $1.00 per share requirement for continued listing on the Nasdaq under Nasdaq Listing Rule 5550(a)(2). In accordance with applicable Nasdaq procedures, the Company has a period of 180 calendar days following the receipt of the written notice mentioned above to cure the deficiency and regain compliance.
- 09/22/2023
|
InMed to Present at H.C. Wainwright 25th Annual Global Investment Conference
- Vancouver, British Columbia--(Newsfile Corp. - September 7, 2023) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the pharmaceutical research, development, manufacturing, and commercialization of rare cannabinoids and cannabinoid analogs, today announce that the company will be participating in the H.C. Wainwright Global Investment Conference, which takes place September 11-13, 2023, in New York City.
- 09/07/2023
|
InMed (INM) Gets Grant to Begin Neurodegenerative Diseases Program
- InMed Pharmaceuticals (INM) surges on receiving research grant funding from the Natural Sciences and Engineering Research Council of Canada (NSERC) to investigate its cannabinoid drug candidates.
- 11/17/2022
|
InMed stock rockets after research grant awarded for cannabinoid analogs to treat Alzheimer's, Parkinson's
- Shares of InMed Pharmaceuticals Inc. INM, +52.16% rocketed 50.9% on very heavy volume in midday trading Wednesday, after the company said it was awarded a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to support research and development of its cannabinoid drug candidates for the potential treatment of neurodegenerative diseases, such as Alzheimer's, Parkinson's and Huntington's. Trading volume spiked to 19.5 million shares, compared with the full-day average of about 148,200 shares.
- 11/16/2022
|
InMed Pharmaceuticals Inc. (INM) Q4 2022 Earnings Call Transcript
- InMed Pharmaceuticals Inc. (NASDAQ:INM ) Q4 2022 Results Conference Call September 23, 2022 1:00 PM ET Company Participants Colin Clancy - VP, IR Eric Adams - President and CEO Michael Woudenberg - COO Brenda Edwards - Interim CFO Dr. Eric Hsu - SVP, Preclinical Research and Development Conference Call Participants Scott Henry - ROTH Capital Partners Raghuram Selvaraju - H.C. Wainwright Operator Good day.
- 09/23/2022
|
InMed Pharmaceuticals to Report Full Year Fiscal 2022 Financial Results and Business Update on September 23, 2022
- VANCOUVER, British Columbia, Sept. 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development and manufacturing of rare cannabinoids, will report financial results on Friday, September 23, 2022 for the fiscal year ended June 30, 2022.
- 09/19/2022
|
Why Is InMed (INM) Stock Up 60% Today?
- The relief rally we've seen play out last week is once again in full focus on Monday. All major indices have moved higher today.
- 09/12/2022
|
InMed Pharmaceuticals (INM) Stock Soars 32% on R&D Updates
- Source: gvictoria / Shutterstock.com InMed Pharmaceuticals (NASDAQ: INM ) stock is rocketing higher on Friday after the company revealed research and development (R&D) updates. According to the cannabis company, it's reevaluating its business to better focus on its core pharmaceutical efforts.
- 09/09/2022
|
Trending Penny Stocks For Your September Watchlist
- Here's what you need to know about trading penny stocks on September 2nd The post Trending Penny Stocks For Your September Watchlist appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 09/02/2022
|
InMed Pharmaceuticals (INM) Stock: 1-For-25 Split Announced
- InMed Pharmaceuticals (INM) announced it will be consolidating all of its issued and outstanding share capital on the basis of 1 for 25 pre‐consolidation common shares of the company. These are the details.
- 08/24/2022
|
9 Cannabis Stocks on Fire This Week
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
- 07/29/2022
|
This Week's Cannabis Stock News: 7 Companies Make Headlines
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
- 06/10/2022
|
The Holiday-Shortened Week Didn't Stop These 8 Cannabis Stocks
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks this week, and look ahead to how the cannabis industry will continue to develop in 2022.
- 06/03/2022
|
InMed Pharmaceuticals Inc. (INM) Reports Q3 Loss, Misses Revenue Estimates
- InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -8.70% and 27.06%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/13/2022
|
InMed to Participate in Upcoming Investor Conferences in April and May 2022
- VANCOUVER, British Columbia, April 19, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, announces that the Company's executive team will be participating in several investor events throughout April and May 2022.
- 04/19/2022
|
InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q2 2022 Results - Earnings Call Transcript
- InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q2 2022 Results - Earnings Call Transcript
- 02/15/2022
|
InMed Pharmaceuticals Inc. (INM) Reports Q2 Loss, Tops Revenue Estimates
- InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of -29.17% and 6%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 02/14/2022
|
InMed Pharmaceuticals to Report Second Quarter Fiscal 2022 Financial Results and Business Update on February 15, 2022
- VANCOUVER, British Columbia, Feb. 10, 2022 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, will report financial results on Tuesday, February 15, 2022 for the second quarter of fiscal year 2022, ending December 31, 2021.
- 02/10/2022
|
8 Cannabis Stocks Ablaze During Christmas Week
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up as we round out 2021.
- 12/27/2021
|
Best Penny Stocks To Buy Now? 5 To Watch Before Next Week
- Are these on your list of penny stocks right now? The post Best Penny Stocks To Buy Now?
- 11/23/2021
|
InMed Pharmaceuticals (INM) Stock: Why The Price Surged Today
- The shares of InMed Pharmaceuticals Inc (NASDAQ: INM) increased by over 49% during intraday trading today. This is why it happened.
- 11/17/2021
|
This Week's Slew of Cannabis Earnings and Breaking News
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update , where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
- 11/12/2021
|
InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss, Lags Revenue Estimates
- InMed Pharmaceuticals Inc. (INM) delivered earnings and revenue surprises of 28.57% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/10/2021
|
InMed Pharmaceuticals Completes Acquisition of BayMedica Creating a Market Leader in the Manufacturing of Rare Cannabinoids
- VANCOUVER, British Columbia and SOUTH SAN FRANCISCO, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that they have completed the previously announced acquisition of BayMedica Inc. (“BayMedica”), a private company based in the US specializing in the manufacturing and commercialization of rare cannabinoids for the health and wellness sector.
- 10/13/2021
|
InMed Pharmaceuticals Announces Commencement of Phase 2 Clinical Trial Investigating Cannabinol (CBN), a Rare Cannabinoid, in the Treatment of Epidermolysis Bullosa
- VANCOUVER, British Columbia, Sept. 30, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that it has commenced its Phase 2 clinical trial of INM-755 (cannabinol) cream in the treatment of Epidermolysis Bullosa (“EB”). This marks the first time cannabinol has advanced to a Phase 2 Clinical trial to be studied as a therapeutic option to treat a disease.
- 09/30/2021
|
InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q4 2021 Results - Earnings Call Transcript
- InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q4 2021 Results - Earnings Call Transcript
- 09/24/2021
|
Cannabinoids Company InMed Pharma Posts Smaller Net Loss For FY21
- InMed Pharmaceuticals Inc (NASDAQ: INM) reported an FY21 EPS loss of $(1.52) narrower than $(1.71) posted a year ago. On June 30, the company's cash, cash equivalents, and short-term investments were $7.4 million.
- 09/24/2021
|
InMed Pharmaceuticals Reports Full Year Fiscal 2021 Financial Results and Provides Business Update
- VANCOUVER, British Columbia, Sept. 24, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today reported financial results for the fiscal year ended June 30, 2021.
- 09/24/2021
|
InMed Pharmaceuticals (INM): Acquiring BayMedica
- LONDON, UK / ACCESSWIRE / September 20, 2021 / InMed has announced that it has entered into a definitive agreement to acquire BayMedica, a private US-based company that is focusing on the manufacture and commercialization of rare cannabinoids. This is an all-stock transaction in which InMed will issue 1.78m shares to BayMedica's equity and convertible debt holders.
- 09/20/2021
|
InMed Pharmaceuticals to Report Full Year Fiscal 2021 Financial Results and Business Update on September 24, 2021
- VANCOUVER, British Columbia, Sept. 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, will report financial results for the fiscal year ended June 30, 2021, on Friday, September 24, 2021.
- 09/17/2021
|
9 Cannabis Stocks Lighting Up The News Cycle
- Welcome back to our weekly series, Schaeffer's Cannabis Stock News Update, where we recap what happened in the world of marijuana stocks and look ahead to how the cannabis industry continues to shape up in 2021.
- 09/17/2021
|
InMed Pharmaceuticals and BayMedica Participating in Tribe Public's Webinar "Accelerating The Commercialization of Rare Cannabinoids"
- Registration for the September 21, 2021 event now open
- 09/17/2021
|
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
- Establishes leadership position in manufacturing and commercialization of rare cannabinoids Positions InMed within large and growing consumer health and wellness cannabinoid markets
- 09/13/2021
|
INM Stock: Why It Increased Today
- The stock price of InMed Pharmaceuticals Inc (NASDAQ: INM) increased over 10% pre-market today. This is why it happened.
- 09/13/2021
|
InMed Pharmaceuticals Signs Definitive Agreement to Acquire BayMedica, a Leading Commercial Manufacturer of Rare Cannabinoids
- VANCOUVER, British Columbia, Sept. 13, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that it has entered into a definitive agreement (“Definitive Agreement”) to acquire BayMedica Inc. (“BayMedica”), a private company based in the US that specializes in the manufacturing and commercialization of rare cannabinoids. The Definitive Agreement follows a previously signed letter of intent (the "LOI") announced on June 29, 2021. The transaction, which is subject to certain standard closing conditions, is expected to close in the coming weeks.
- 09/13/2021
|
InMed Pharmaceuticals to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
- VANCOUVER, British Columbia, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a leader in the manufacturing and clinical development of rare cannabinoids, today announced that Eric. A. Adams, President and CEO of InMed will present at the H.C. Wainwright 23rd Annual Global Investment Conference which is being held virtually from September 13-15, 2021.
- 09/09/2021
|
InMed Pharmaceuticals Inc. (NASDAQ: INM) Pursues Commercial Production Of Rare Cannabinoids At Pharmaceutical Levels
- Canadian clinical-stage drug development company InMed Pharmaceuticals is working to achieve pharmaceutical approval of rare cannabinoids
- 08/25/2021
|
InMed Pharmaceuticals to Present at the H.C. Wainwright Ophthalmology Virtual Conference
- VANCOUVER, British Columbia, Aug. 12, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that Eric. A. Adams, President and CEO, and Dr. Eric Hsu, Senior Vice President of Pre-Clinical Research & Development, will present at H.C. Wainwright Ophthalmology Virtual Conference on Tuesday, August 17, 2021.
- 08/12/2021
|
InMed Pharmaceuticals Announces Closing of US$12 Million Private Placement Priced At-the-Market under Nasdaq Rules
- VANCOUVER, British Columbia, July 02, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that it has closed the previously announced private placement.
- 07/02/2021
|
InMed Pharmaceuticals Increases Cannabinoid Yield to 5 g/L with IntegraSyn™ in Advance of Commercial Scale Production
- VANCOUVER, British Columbia, June 17, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates as well as manufacturing technologies for pharmaceutical-grade rare cannabinoids, today announced that its continued optimization of IntegraSyn™ has increased the cannabinoid yield to a level of 5 g/L, further improving the economics of this proprietary manufacturing approach in advance of large-scale production.
- 06/17/2021
|
InMed Pharmaceuticals to Present at the 2021 BIO Digital Conference
- VANCOUVER, British Columbia, June 09, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will present at 2021 BIO Digital, the premier biotech conference, which is being held virtually this year from June 10-11 and 14-18, 2021.
- 06/09/2021
|
InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q3 2021 Results - Earnings Call Transcript
- InMed Pharmaceuticals Inc. (INM) CEO Eric Adams on Q3 2021 Results - Earnings Call Transcript
- 05/16/2021
|
InMed Pharmaceuticals Reports Third Quarter Fiscal 2021 Financial Results
- VANCOUVER, British Columbia, May 13, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical development of cannabinol (“CBN”), today reported financial results for the third quarter of fiscal year 2021 (“3Q21”) which ended March 31, 2021.
- 05/13/2021
|
InMed to Present at Canaccord Genuity's 5th Annual Global Cannabis Conference on May 11th, 2021
- VANCOUVER, British Columbia, May 04, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and leading the clinical development of cannabinol (“CBN”), today announced that Eric. A. Adams, President and CEO of InMed, will be presenting at Canaccord Genuity's 5th Annual Global Cannabis Conference on Tuesday, May 11th, which is being held virtually this year. Details on the conference and how to participate are below.
- 05/04/2021
|
InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa
- VANCOUVER, British Columbia, April 28, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a world leader in the clinical development of cannabinol (“CBN”), today announced that it has filed Clinical Trial Applications (“CTAs”) in Austria, Israel and Serbia as part of a Phase 2 clinical trial of INM-755 (cannabinol) cream in Epidermolysis Bullosa (“EB”). Additional CTAs for 755-201-EB (the ‘201 study) will be submitted to National Competent Authorities (“NCAs”) and Ethics Committees (“ECs”) in France, Germany, Greece, and Italy in the coming weeks.
- 04/28/2021
|
InMed Pharmaceuticals Announces Voluntary Delisting from TSX
- All common shares will continue to be listed and tradable on the Nasdaq All common shares will continue to be listed and tradable on the Nasdaq
- 04/27/2021
|
InMed Pharmaceuticals Synthesizes Rare Cannabinoids To Treat Glaucoma, Skin Disease
- InMed Pharmaceuticals went public last November.
- 04/12/2021
|
InMed to Present at Virtual Conferences in March 2021
- VANCOUVER, British Columbia, March 03, 2021 (GLOBE NEWSWIRE) -- InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM; TSX:IN), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates targeting diseases with high unmet medical need and leading the clinical development of cannabinol (“CBN”), today announced that Eric A. Adams, President and CEO of InMed, will be presenting at investor conferences in March 2021. The details of each conference are included below.
- 03/03/2021
|
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results
- VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of...
- 02/05/2021
|
InMed Pharmaceuticals Stock Drops After It Presses Capital Raise Button
- InMed Pharmaceuticals Inc (NASDAQ: INM) has entered into definitive agreements with certain institutional investors to raise approximately $4.5 million at $4.25 per unit in a private placement. Each unit consists of one common share and 0.66 of a warrant to purchase one common share.
- 02/05/2021
|
InMed Announces US$4.5 Million Private Placement
- VANCOUVER, BC, Feb. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol...
- 02/05/2021
|
InMed Pharmaceuticals to Participate in 2021 Cannabinoid-Derived Pharmaceuticals Industry Review Summit Europe
- InMed's Michael Woudenberg, Karen Long & Prof. Mauro Maccarrone among Expert Speakers VANCOUVER, BC, Jan. 19, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ:INM) (TSX:IN), a clinical-stage pharmaceutical company developing medications targeting diseases...
- 01/19/2021
|
InMed Announces Results of Second Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects
- TSX: IN NASDAQ: INM VANCOUVER, BC, Jan. 8, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical...
- 01/08/2021
|
InMed to Participate at Virtual Conferences in January 2021
- VANCOUVER, BC, Jan. 5, 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the clinical development of cannabinol...
- 01/05/2021
|
